Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.

Lehmann TP, Wrzesiński T, Jagodziński PP.

Mol Med Rep. 2013 Mar;7(3):893-900. doi: 10.3892/mmr.2012.1244. Epub 2012 Dec 18.

PMID:
23254310
2.

Tumor necrosis factor-alpha regulates steroidogenesis, apoptosis, and cell viability in the human adrenocortical cell line NCI-H295R.

Mikhaylova IV, Kuulasmaa T, Jääskeläinen J, Voutilainen R.

Endocrinology. 2007 Jan;148(1):386-92. Epub 2006 Oct 12.

PMID:
17038555
3.

Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.

van Koetsveld PM, Vitale G, Feelders RA, Waaijers M, Sprij-Mooij DM, de Krijger RR, Speel EJ, Hofland J, Lamberts SW, de Herder WW, Hofland LJ.

Endocr Relat Cancer. 2013 May 30;20(3):443-54. doi: 10.1530/ERC-12-0217. Print 2013 Jun.

4.

The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.

Hescot S, Paci A, Seck A, Slama A, Viengchareun S, Trabado S, Brailly-Tabard S, Al Ghuzlan A, Young J, Baudin E, Lombès M.

Horm Cancer. 2014 Oct;5(5):312-23. doi: 10.1007/s12672-014-0189-7. Epub 2014 Jul 16.

5.

Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.

Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M.

Endocrinology. 2015 Nov;156(11):3895-908. doi: 10.1210/en.2015-1367. Epub 2015 Aug 25.

PMID:
26305886
6.

Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells.

Lin CW, Chang YH, Pu HF.

Toxicology. 2012 Aug 16;298(1-3):14-23. doi: 10.1016/j.tox.2012.04.007. Epub 2012 Apr 23.

PMID:
22546480
7.

Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway.

Wu CH, Chen YF, Wang JY, Hsieh MC, Yeh CS, Lian ST, Shin SJ, Lin SR.

Br J Cancer. 2002 Oct 21;87(9):1000-5.

9.

Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.

Ragazzon B, Cazabat L, Rizk-Rabin M, Assie G, Groussin L, Fierrard H, Perlemoine K, Martinez A, Bertherat J.

Cancer Res. 2009 Sep 15;69(18):7278-84. doi: 10.1158/0008-5472.CAN-09-1601. Epub 2009 Sep 8.

10.

Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells.

Hescot S, Slama A, Lombès A, Paci A, Remy H, Leboulleux S, Chadarevian R, Trabado S, Amazit L, Young J, Baudin E, Lombès M.

Endocr Relat Cancer. 2013 May 21;20(3):371-81. doi: 10.1530/ERC-12-0368. Print 2013 Jun.

11.

Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.

Stigliano A, Cerquetti L, Borro M, Gentile G, Bucci B, Misiti S, Piergrossi P, Brunetti E, Simmaco M, Toscano V.

Endocr Relat Cancer. 2008 Mar;15(1):1-10. doi: 10.1677/ERC-07-0003.

12.

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libé R, Allolio B, Bertagna X, Bertherat J, Beuschlein F, Fassnacht M, Karavitaki N, Mannelli M, Mantero F, Opocher G, Porfiri E, Quinkler M, Sherlock M, Terzolo M, Nightingale P, Shackleton CH, Stewart PM, Hahner S, Arlt W.

J Clin Endocrinol Metab. 2013 Jan;98(1):161-71. doi: 10.1210/jc.2012-2851. Epub 2012 Nov 16.

PMID:
23162091
13.

Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines.

Gentilin E, Molè D, Gagliano T, Minoia M, Ambrosio MR, Degli Uberti EC, Zatelli MC.

Reprod Toxicol. 2014 Jun;45:71-6. doi: 10.1016/j.reprotox.2014.01.008. Epub 2014 Jan 31.

PMID:
24486453
17.

Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids.

Rainey WE, Bird IM, Sawetawan C, Hanley NA, McCarthy JL, McGee EA, Wester R, Mason JI.

J Clin Endocrinol Metab. 1993 Sep;77(3):731-7.

PMID:
8396576
18.

Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis.

Johnsen IK, Kappler R, Auernhammer CJ, Beuschlein F.

Cancer Res. 2009 Jul 15;69(14):5784-92. doi: 10.1158/0008-5472.CAN-08-4428. Epub 2009 Jul 7.

19.

Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.

Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P, Brunetti E, Toscano V, Stigliano A.

Endocr Relat Cancer. 2008 Jun;15(2):623-34. doi: 10.1677/erc.1.1315.

20.

Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.

Gagliano T, Gentilin E, Benfini K, Di Pasquale C, Tassinari M, Falletta S, Feo C, Tagliati F, Uberti ED, Zatelli MC.

Endocrine. 2014 Dec;47(3):943-51. doi: 10.1007/s12020-014-0374-z. Epub 2014 Aug 6.

PMID:
25096913

Supplemental Content

Support Center